Comparative Pharmacology
Head-to-head clinical analysis: BENZTHIAZIDE versus DYAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZTHIAZIDE versus DYAZIDE.
BENZTHIAZIDE vs DYAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium reabsorption and increasing excretion of water, sodium, chloride, potassium, and hydrogen ions. Also causes vasodilation via direct arteriolar relaxation.
Dyazide is a combination of hydrochlorothiazide, a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal convoluted tubule, reducing sodium and water reabsorption; and triamterene, a potassium-sparing diuretic that blocks epithelial sodium channels in the collecting duct, reducing potassium excretion.
Adults: 25-50 mg orally once daily initially, may increase to 100 mg daily in a single dose or two divided doses. Maximum dose: 100 mg/day.
1-2 capsules orally once daily; each capsule contains hydrochlorothiazide 25 mg and triamterene 50 mg.
None Documented
None Documented
Clinical Note
moderateBenzthiazide + Mecamylamine
"The risk or severity of adverse effects can be increased when Benzthiazide is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Benzthiazide
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Benzthiazide."
Terminal elimination half-life: 8-12 hours; clinical context: supports once-daily dosing for hypertension, but duration of action may extend beyond half-life due to tissue distribution.
Triamterene: 1.5–2.5 hours; hydrochlorothiazide: 6–15 hours. Clinical dosing typically once daily.
Renal: ~90% (60% unchanged, 30% as glucuronide conjugate); biliary/fecal: minimal (<5%).
Renal: triamterene ~80% (as metabolites and parent), hydrochlorothiazide >95% unchanged.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic